Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Mol Biol Rep ; 51(1): 640, 2024 May 10.
Article in English | MEDLINE | ID: mdl-38727848

ABSTRACT

Memory issues are a prevalent symptom in different neurodegenerative diseases and can also manifest in certain psychiatric conditions. Despite limited medications approved for treating memory problems, research suggests a lack of sufficient options in the market. Studies indicate that a significant percentage of elderly individuals experience various forms of memory disorders. Metformin, commonly prescribed for type 2 diabetes, has shown neuroprotective properties through diverse mechanisms. This study explores the potential of metformin in addressing memory impairments. The current research gathered its data by conducting an extensive search across electronic databases including PubMed, Web of Science, Scopus, and Google Scholar. Previous research suggests that metformin enhances brain cell survival and memory function in both animal and clinical models by reducing oxidative stress, inflammation, and cell death while increasing beneficial neurotrophic factors. The findings of the research revealed that metformin is an effective medication for enhancing various types of memory problems in numerous studies. Given the rising incidence of memory disorders, it is plausible to utilize metformin, which is an affordable and accessible drug. It is often recommended as a treatment to boost memory.


Subject(s)
Memory Disorders , Metformin , Metformin/therapeutic use , Metformin/pharmacology , Memory Disorders/drug therapy , Humans , Animals , Oxidative Stress/drug effects , Neuroprotective Agents/therapeutic use , Neuroprotective Agents/pharmacology , Memory/drug effects , Hypoglycemic Agents/pharmacology , Hypoglycemic Agents/therapeutic use , Brain/drug effects , Brain/metabolism
2.
Adv Protein Chem Struct Biol ; 129: 51-90, 2022.
Article in English | MEDLINE | ID: mdl-35305725

ABSTRACT

Cervical cancer, the fourth most frequent women cancer worldwide, is mostly (about 99%) associated with human papillomavirus (HPV). Despite availability of three effective prophylactic vaccines for more than one decade and some other preventive measures, it is still the fourth cause of cancer death among women globally. Thus, development of therapeutic vaccines seems essential, which has been vastly studied using different vaccine platforms. Even with very wide efforts during the past years, no therapeutic vaccine has been approved yet, which might be partly due to the complex events and interactions taken place in the tumor microenvironment. On the other hand, immunotherapy has opened its way into the management plans of some cancers. The recent approval of pembrolizumab for the treatment of metastatic/recurrent cervical cancer brings new hopes to the management of this disease, while some other immunotherapeutic approaches are also under investigation either alone or in combination with vaccines. Here, following a summary about HPV and its pathogenesis, cervical cancer therapeutic vaccines would be reviewed. Cell-based vaccines as well as immunomodulation and other modalities used along with vaccines would be also discussed.


Subject(s)
Alphapapillomavirus , Papillomavirus Infections , Papillomavirus Vaccines , Uterine Cervical Neoplasms , Female , Humans , Immunotherapy , Male , Papillomaviridae , Papillomavirus Infections/complications , Papillomavirus Infections/therapy , Papillomavirus Vaccines/therapeutic use , Tumor Microenvironment , Uterine Cervical Neoplasms/prevention & control
SELECTION OF CITATIONS
SEARCH DETAIL
...